Compare Suven Life Sciences with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES STRIDES PHARMA SCIENCE SUVEN LIFE SCIENCES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -83.2 47.4 - View Chart
P/BV x 1.3 2.2 59.0% View Chart
Dividend Yield % 1.8 0.2 801.6%  

Financials

 SUVEN LIFE SCIENCES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
SUVEN LIFE SCIENCES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3381,147 29.4%   
Low Rs169642 26.4%   
Sales per share (Unadj.) Rs52.1317.2 16.4%  
Earnings per share (Unadj.) Rs6.87.8 87.1%  
Cash flow per share (Unadj.) Rs8.625.1 34.2%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.60.2 264.6%  
Book value per share (Unadj.) Rs65.3274.3 23.8%  
Shares outstanding (eoy) m127.2889.50 142.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.92.8 172.5%   
Avg P/E ratio x37.1114.0 32.6%  
P/CF ratio (eoy) x29.635.7 82.9%  
Price / Book Value ratio x3.93.3 119.1%  
Dividend payout %22.025.5 86.1%   
Avg Mkt Cap Rs m32,27280,058 40.3%   
No. of employees `0001.12.5 43.2%   
Total wages/salary Rs m6614,341 15.2%   
Avg. sales/employee Rs Th6,132.211,325.8 54.1%   
Avg. wages/employee Rs Th611.11,731.4 35.3%   
Avg. net profit/employee Rs Th803.5280.1 286.9%   
INCOME DATA
Net Sales Rs m6,63528,394 23.4%  
Other income Rs m242941 25.8%   
Total revenues Rs m6,87729,334 23.4%   
Gross profit Rs m1,6043,965 40.5%  
Depreciation Rs m2211,540 14.4%   
Interest Rs m381,962 1.9%   
Profit before tax Rs m1,5871,403 113.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m71897 737.9%   
Profit after tax Rs m869702 123.8%  
Gross profit margin %24.214.0 173.1%  
Effective tax rate %45.26.9 652.3%   
Net profit margin %13.12.5 529.9%  
BALANCE SHEET DATA
Current assets Rs m6,23224,836 25.1%   
Current liabilities Rs m1,49018,993 7.8%   
Net working cap to sales %71.520.6 347.3%  
Current ratio x4.21.3 319.8%  
Inventory Days Days8671 121.8%  
Debtors Days Days83113 72.8%  
Net fixed assets Rs m4,04334,289 11.8%   
Share capital Rs m127895 14.2%   
"Free" reserves Rs m8,18323,651 34.6%   
Net worth Rs m8,31024,546 33.9%   
Long term debt Rs m1815,513 0.1%   
Total assets Rs m10,38965,437 15.9%  
Interest coverage x43.11.7 2,513.4%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.60.4 147.2%   
Return on assets %8.74.1 214.4%  
Return on equity %10.52.9 365.8%  
Return on capital %19.56.9 283.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62215,697 35.8%   
Fx outflow Rs m1,799735 244.7%   
Net fx Rs m3,82214,962 25.5%   
CASH FLOW
From Operations Rs m3561,871 19.0%  
From Investments Rs m-2795,826 -4.8%  
From Financial Activity Rs m-225-10,157 2.2%  
Net Cashflow Rs m-148-2,615 5.7%  

Share Holding

Indian Promoters % 63.4 27.7 228.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 25.9 140.9%  
Shareholders   37,287 56,241 66.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  NEULAND LABS  

Compare SUVEN LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 440 Points Higher; Nestle India and ACC Among Top Stocks in Focus(09:30 am)

Asian stock markets are trading on a mixed note today as investors await the release of China's latest benchmark lending rate.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 20, 2021 10:00 AM

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES - ORCHID PHARMA COMPARISON

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS